Please login to the form below

Not currently logged in

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

BMS building

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis

Merck and Ridgeback request EUA from US FDA for COVID-19 drug molnupiravir

Merck & Co HQIf authorised, molnupiravir could be the first oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in at risk adults

bluebird bio provides update on 2seventy bio spin-off

Bluebird BioThe company has also announced the appointment of two new board members, Najoh Tita-Reid and Sarah Glickman

World Mental Health Day is on 10 October

World Mental Health DayYou Okay, Doc? A call for more awareness and support for the mental health of doctors

Merck to acquire Acceleron in a deal worth around $11.5bn

Merck & Co HQThe acquisition of the biopharmaceutical company will complement and strengthen Merck’s cardiovascular pipeline

Rocky start for Biogen’s Alzheimer’s drug Aduhelm

Biogen Idec buildingControversial Alzheimer’s treatment Aduhelm is struggling to realise its potential, with only 100 patients receiving the therapy so far in the US

Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%

GileadNew data showing Gilead’s Veklury cuts the risk of hospitalisation for COVID-19 contradicts results of the World Health Organization’s Solidarity study

AstraZeneca chooses Ireland for $360m manufacturing site

AZ NEWThe next-generation facility will make small molecule active ingredients, future-proofing the company’s supply chain and boosting the Irish life sciences sector

New data for Tecentriq in early-stage lung cancer

Roche Basel SwitzerlandRoche’s PD-L1 blocker reduced the risk of disease recurrence and death for patients with stage 2-3a non-small cell lung cancer following surgery

Italys digital therapeuticsItaly accelerates the path towards digital therapeutics implementation

PME talks to Roberto Ascione, Gualberto Gussoni and Giuseppe Recchia about the advancement of digital therapeutics in Italy

COVID-19 Updates and Daily News

Featured jobs


Add my company

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?